ADIL — Adial Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $7.22m
- $2.62m
- 10
- 25
- 49
- 16
Annual income statement for Adial Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 10.9 | 19.3 | 10.9 | 6.89 | 8.28 |
| Operating Profit | -10.9 | -19.3 | -10.9 | -6.89 | -8.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.9 | -19.5 | -10.8 | -7 | -13.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.9 | -19.4 | -10.8 | -7 | -13.2 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -10.9 | -19.4 | -12.7 | -5.12 | -13.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.9 | -19.4 | -12.7 | -5.12 | -13.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -21.9 | -24.8 | -10.8 | -4.91 | -2.72 |